Drug Profile
Paliperidone - Johnson & Johnson
Alternative Names: 9-hydroxyrisperidone; Invega; JNS-007ER; Paliperidone controlled release; Paliperidone ER; Paliperidone ER OROS; R0-76477; RO-76477Latest Information Update: 01 Jul 2020
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Developer Janssen Pharmaceutical KK; Johnson & Johnson
- Class 2 ring heterocyclic compounds; Antipsychotics; Fluorobenzenes; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Aggression; Agitation; Schizoaffective disorder; Schizophrenia
- Discontinued Bipolar disorders; Insomnia; Manic episodes
Most Recent Events
- 04 Mar 2020 Janssen-Cilag completes the phase III trial for Schizophrenia in Belgium, Bulgaria, Croatia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Latvia, Lithuania, Netherlands, Poland, Portugal, Russia, Serbia, Spain, Sweden, Switzerland, Turkey and United Kingdom (NCT00460512)
- 05 Mar 2015 No recent reports on development identified - Phase-III for Schizophrenia (In adolescents) in India, Russia, South Korea and Ukraine (PO)
- 04 Jun 2014 Registered for Schizophrenia (in adolescents aged 15 years and older) in European Union (PO)